@article{3120554,
    title = "Cancer therapy and the heart; the necessity to calibrate risk",
    author = "Okwuosa, T.M. and Keramida, K. and Filippatos, G. and Yancy, C.W.",
    journal = "European Journal of Heart Failure",
    year = "2020",
    volume = "22",
    number = "11",
    pages = "1961-1965",
    publisher = "John Wiley and Sons Ltd",
    doi = "10.1002/ejhf.1999",
    keywords = "anthracycline;  antiandrogen;  antineoplastic agent;  immune checkpoint inhibitor;  immunomodulating agent;  mitogen activated protein kinase kinase inhibitor;  phosphotransferase inhibitor;  proteasome inhibitor;  protein inhibitor;  Raf protein inhibitor;  unclassified drug;  vasculotropin inhibitor, algorithm;  cancer chemotherapy;  cancer patient;  cardiologist;  cardiotoxicity;  cardiovascular disease;  cardiovascular risk;  childhood cancer;  cytology;  delayed diagnosis;  disease risk assessment;  drug exposure;  echocardiography;  Editorial;  genomics;  heart arrhythmia;  heart failure;  heart injury;  high risk patient;  human;  hypertension;  ischemia;  malignant neoplasm;  medical expert;  metabolic syndrome X;  myocarditis;  oncologist;  practice guideline;  priority journal;  proteomics;  QT prolongation;  risk assessment;  risk benefit analysis;  risk management;  risk reduction;  shared decision making;  therapy delay;  thromboembolism;  cardiology;  cardiovascular disease;  heart failure;  neoplasm;  risk factor, Cardiology;  Cardiovascular Diseases;  Heart Disease Risk Factors;  Heart Failure;  Humans;  Neoplasms;  Risk Assessment;  Risk Factors"
}